award

Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers

  • Award Number: R01CA262530

  • ORGANIZATION: NATIONAL CANCER INSTITUTE

  • OPDIV: NIH

  • AWARD CLASS: DISCRETIONARY

  • AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

  • PERIOD OF PERFORMANCE START DATE: 07/12/2021

  • PERIOD OF PERFORMANCE END DATE: 06/30/2026